KeyBanc lowered the firm’s price target on Schrodinger (SDGR) to $25 from $28 and keeps an Overweight rating on the shares. Coming off a choppy year for HCIT stocks, fundamentally, the firm did see a “year of inflection” for many of its names with estimate revisions plus valuations largely bottoming. While KeyBanc expects momentum to continue for most of its coverage, the firm does see valuation multiples impacted by competition concerns and regulatory impacts.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SDGR:
- Schrodinger initiated with a Neutral at UBS
- BofA shakes up ratings in Biopharma Services with seven changes
- Schrodinger upgraded to Buy from Neutral at BofA
- Cathie Wood’s ARK Investment buys 36.6K shares of Schrodinger today
- FDA guides on streamlined nonclinical monoclonal antibody safety studies